Wednesday, June 25, 2025

Viz.ai & Guardant Health Partner to Enhance Lung Cancer Care

Related stories

Digital Science launches AI writing tools for Overleaf users

Digital Science announced the launch of AI Assist, an...

Centific and Virtue AI team up on responsible AI by Design

This integration delivers 30x faster multimodal protection enabling full-stack...

Vultr Gets $329M to Expand Global AI and Cloud Platform

Vultr secures $329M in credit financing to boost global...

Okta Adds Cross App Access to Secure enterprise AI Agents

Okta launches Cross App Access, a new OAuth-based protocol...

SWARM Biotactics Raises €13M to Advance Bio-Robotics

SWARM Biotactics, developer of bio-robotic systems based on fully...
spot_imgspot_img

Proposed collaboration aims to integrate cutting-edge AI and genomic insights to advance guideline-directed medical therapy

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, announced a proposed collaboration with Guardant Health, Inc., a leading precision oncology company, to address challenges in lung cancer care. The collaboration aims to help oncologists diagnose lung cancer earlier and make more informed treatment decisions to improve patient outcomes, reflecting the companies’ shared commitment to leveraging technology to close critical gaps in cancer care and streamline the patient journey.

“This collaboration represents a promising step forward in the fight against lung cancer and reflects our commitment to expanding Viz.ai’s impact in oncology,” said Dr. Chris Mansi, CEO and co-founder at Viz.ai. “Together, we have the opportunity to harness the power of AI and genomics to ensure patients receive timely, personalized, and effective care.”

Also Read: Atropos Health Boosts Precision Medicine with AI Models

Nearly 40% of lung cancer patients are estimated not to be receiving guideline-directed medical therapy.1 Delays in diagnosis, testing, and appropriate treatment increase the risk of lung cancer progression to advanced-stage disease and can contribute to higher mortality rates. The intent of the proposed collaboration between Viz.ai and Guardant is to address clinical practice gaps along the lung cancer patient journey by facilitating timely biomarker testing with the Guardant360® CDx liquid biopsy, thereby accelerating time to precision diagnosis and optimal treatment selection.

The Viz.ai One platform leverages machine learning algorithms to analyze data from imaging, the EHR and other tests and deliver real-time, actionable insights and automated assessments to accelerate diagnosis and treatment. Viz.ai acts as a safety net in 1,700 hospitals to automatically identify patients with disease and direct them to the right specialist and the right treatment.

Source: Businesswire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img